Publication Name	World Journal of Hepatology
Manuscript ID	64582
Country	Thailand

Received	2021-02-21 06:43
Peer-Review Started	2021-02-21 06:46
First Decision by Editorial Office Director	2021-05-03 01:14
Return for Revision	2021-05-03 01:14
Revised	2021-05-07 11:08
Publication Fee Transferred
Second Decision by Editor	2021-07-28 05:09
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-07-28 08:39
Articles in Press	2021-07-28 08:39
Edit the Manuscript by Language Editor	2021-08-11 01:59
Typeset the Manuscript	2021-09-17 00:15
Publish the Manuscript Online	2021-09-22 08:09

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Challenges in the discontinuation of chronic hepatitis B antiviral agent
Manuscript Source	Invited Manuscript
All Author List	Apichat Kaewdech and Pimsiri Sripongpun
ORCID	Author(s) ORCID Number Apichat Kaewdech http://orcid.org/0000-0002-4058-5977 Pimsiri Sripongpun http://orcid.org/0000-0003-0007-8214
Funding Agency and Grant Number
Corresponding Author	Pimsiri Sripongpun, MD, Assistant Professor, Department of Internal Medicine, aculty of Medicine, Prince of Songkla University, 15 Kanchanavanich Road, Hat Yai 90110, Songkhla, Thailand. spimsiri@medicine.psu.ac.th
Key Words	Viral hepatitis B; Relapse; Re-treatment; SCALE-B; Stop treatment strategy; Nucleoside analogs
Core Tip	Stop strategy is one of the options to get closer to functional cure with finite duration of treatment in chronic hepatitis B patients. Virological relapse and clinical relapse (CR) are common after stopping antiviral agent. A half of patients with CR required re-treatment. Novel biomarkers and SCALE-B could predict CR and hepatitis B surface antigen clearance. When to re-start treatment and sensitive novel biomarkers are unmet needs.
Publish Date	2021-09-22 08:09
Citation	Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agent. World J Hepatol 2021; 13(9): 1042-1057
URL	https://www.wjgnet.com/1948-5182/full/v13/i9/1042.htm
DOI	https://dx.doi.org/10.4254/wjh.v13.i9.1042

Full Article (PDF)	WJH-13-1042.pdf
Full Article (Word)	WJH-13-1042.docx
Manuscript File	64582-Review-FilipodiaCL.docx
Answering Reviewers	64582-Answering reviewers.pdf
Audio Core Tip	64582-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64582-Conflict-of-interest statement.pdf
Copyright License Agreement	64582-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	64582-Language certificate.pdf
Peer-review Report	64582-Peer-review(s).pdf
Scientific Misconduct Check	64582-Bing-Wang JL-1.jpg
Scientific Misconduct Check	64582-Bing-Fan JR-2.png
Scientific Misconduct Check	64582-Scientific misconduct check.pdf
Scientific Editor Work List	64582-Scientific editor work list.pdf
CrossCheck Report	64582-CrossCheck report.pdf
CrossCheck Report	64582-CrossCheck.png